10 results
PrimaryPart 1: - To determine the respiratory response of low and high doses of GAL-021 in conjunction with a low dose of opioids and hypercapnia in healthy subjects. Part 2: - To determine the respiratory response of low and high doses of GAL-021…
The aim of the present study is to investigate the differences in patient and endoscopist satisfaction and experiences and patient*s safety with different sedation protocols.
The aim of this study is to determine the patients* and endoscopists experiences and patients* safety with different sedation protocols.
Primary Objective: To evaluate whether a single intravenous alfentanil bolus (7.5 mcg/kg) has a clinically significant analgesic effect in clinical patients who undergo an elective CT-colonography compared to placebo. We have defined a clinically…
Here we will perform a proof of concept study on the ability of the antidepressant tianeptine to prevent respiratory depression from the opioid alfentanil in humans.
The purpose of this clinical investigation is to evaluate the effectiveness of modified Sensor designs on the longevity (up to a maximum of 90 days) of the Senseonics Continuous Glucose Monitoring (CGM) System. The investigation will also evaluate…
The purpose of this study is testing a respiratory stimulant, doxapram. Painkillers such as morphine and alfentanil mute breathing. This is often undesirable, especially in patients. To counteract this attenuation is often used drugs also take away…
The aim of this study is to demonstrate that procedural sedation with propofol and esketamine is more effective and will result in less cardiopulmonary depression than sedation with propofol and the opioid alfentanil. Less side effects should also…
The primary objective of this study is to assess whether abelacimab is non-inferior to apixaban for preventing VTE recurrence at 6 months postrandomization in patients with cancer and recently diagnosed VTE. If noninferiority is demonstrated, then…
The primary objective of this study is to assess whether abelacimab is non-inferior to dalteparin for preventing VTE recurrence through 6 monthspost randomization in patients with GI or GU cancer and recently diagnosed VTE. If non-inferiority is…